Lemaitre Vascular Inc (NASDAQ: LMAT)

LeMaitre Vascular Inc. (LMAT), a prominent player in the medical devices and human tissue cryopreservation services industry, is dedicated to the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company's primary focus is on developing, manufacturing, and marketing devices that cater to the needs of vascular surgeons and other specialists such as cardiac surgeons, general surgeons, and neurosurgeons. LeMaitre's diverse portfolio of devices includes brand-name products that are widely recognized and used in arteries and veins.

LeMaitre's main business activities revolve around the provision of biologic products and allograft cryopreservation services. The company's biologic products, including XenoSure, CardioCel, and VascuCel patches, are used in various vascular reconstructions such as peripheral bypass, hemodialysis access, and aortic infections, as well as in cardiac repair and reconstruction. On the other hand, LeMaitre's allograft cryopreservation services, such as RestoreFlow, preserve the integrity and functionality of human tissue for use in surgical procedures.

The company's revenue is primarily generated from the sales of its biologic products and allograft cryopreservation services. LeMaitre's products are used in various procedures, including in situ bypass, carotid endarterectomy, and interrupted anastomosis. The company's products are sold globally, with a direct sales force of 136 representatives, including three export managers, in key regions such as the United States, Europe, Canada, and Asia Pacific.

In a highly competitive industry, LeMaitre competes with larger companies such as Abbott, Baxter International, Inc., Artivion, Becton, Dickinson and Company, Edwards Lifesciences Corporation, Getinge, LifeNet Health, Silk Road Medical, Terumo Medical Corporation, and W. L. Gore & Associates. Despite the competition, LeMaitre is well-positioned to capture an increasing share of the market due to its strong brands, established sales force, and broad network of vascular surgeon customers.

LeMaitre's customer base includes over 22,000 vascular surgeons worldwide. The company sells its products primarily through a direct sales force, with approximately 96% of its net sales generated in territories where it employs direct sales representatives.

LeMaitre's brand names and trade names of its products and services include XenoSure, CardioCel, VascuCel, and RestoreFlow. These products are designed to provide a biological solution for vascular reconstruction and preserve the integrity and functionality of allograft tissue for use in surgical procedures.